GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Cash Receipts from Loans

Mersana Therapeutics (STU:0M4) Cash Receipts from Loans


View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Cash Receipts from Loans?

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.


Mersana Therapeutics Business Description

Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.